Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance

<b>The Aim:</b> Determination of the effectiveness of moxifloxacin instead of pyrazinamide in the intensive phase of chemotherapy in patients with newly diagnosed pulmonary TB with monoresistance to pyrazinamide or its intolerance. <b>Materials and methods:</b> Our study included 64 patients with destructive newly diagnosed pulmonary TB with bacterial excretion. Patients were divided into two groups: 1st - 34 patients who received oral moxifloxacin instead of pyrazinamide during the intensive phase of treatment (2 months) and 2nd - 30 patients who received standard treatment regimen. <b>Results:</b> After 4 weeks of treatment, cessation of bacterial excretion by microscopy was observed in 23 (67.6%) patients of group 1 and 16 (53.3%) of group 2 (p &gt;0.05). After 8 weeks, the cessation of bacterial excretion was observed microscopically in 31 (91.2%) patients in the 1st group and 24 (80%) patients in the 2nd group (p &gt; 0.05). Closure of destructions after completion of the intensive phase of treatment was observed in 12 (35.2%) patients of the 1st group and in 9 (30%) in the 2nd group (p &gt;0.05). <b>Conclusions:</b> Replacement of pyrazinamide with moxifloxacin does not reduce the efficacy of treatment compared to standard chemotherapy but may be an alternative in the treatment in case of monoresistance to pyrazamide or its intolerance.